JP2022513668A5 - - Google Patents

Info

Publication number
JP2022513668A5
JP2022513668A5 JP2021530875A JP2021530875A JP2022513668A5 JP 2022513668 A5 JP2022513668 A5 JP 2022513668A5 JP 2021530875 A JP2021530875 A JP 2021530875A JP 2021530875 A JP2021530875 A JP 2021530875A JP 2022513668 A5 JP2022513668 A5 JP 2022513668A5
Authority
JP
Japan
Application number
JP2021530875A
Other languages
Japanese (ja)
Other versions
JP2022513668A (ja
JP7649239B2 (ja
JPWO2020113224A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064032 external-priority patent/WO2020113224A2/en
Publication of JP2022513668A publication Critical patent/JP2022513668A/ja
Publication of JPWO2020113224A5 publication Critical patent/JPWO2020113224A5/ja
Publication of JP2022513668A5 publication Critical patent/JP2022513668A5/ja
Priority to JP2024168470A priority Critical patent/JP2025011142A/ja
Application granted granted Critical
Publication of JP7649239B2 publication Critical patent/JP7649239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021530875A 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法 Active JP7649239B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024168470A JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773885P 2018-11-30 2018-11-30
US62/773,885 2018-11-30
US201962826462P 2019-03-29 2019-03-29
US62/826,462 2019-03-29
PCT/US2019/064032 WO2020113224A2 (en) 2018-11-30 2019-12-02 Chimeric antigen receptor factories and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024168470A Division JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Publications (4)

Publication Number Publication Date
JP2022513668A JP2022513668A (ja) 2022-02-09
JPWO2020113224A5 JPWO2020113224A5 (https=) 2023-04-14
JP2022513668A5 true JP2022513668A5 (https=) 2023-04-14
JP7649239B2 JP7649239B2 (ja) 2025-03-19

Family

ID=70853578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法
JP2024168470A Pending JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024168470A Pending JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Country Status (7)

Country Link
US (1) US12577311B2 (https=)
EP (1) EP3887509A4 (https=)
JP (2) JP7649239B2 (https=)
KR (1) KR20210135475A (https=)
AU (1) AU2019387566A1 (https=)
CA (1) CA3119644A1 (https=)
WO (1) WO2020113224A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
CN109401969B (zh) * 2018-12-13 2024-02-02 珠海西格膜生物技术有限公司 一种细胞工厂的管道连接系统及其使用方法
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
US20220249640A1 (en) * 2019-06-14 2022-08-11 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
EP4226972A4 (en) * 2020-10-12 2025-01-01 Nanjing Iaso Biotechnology Co., Ltd. CD70-BINDING ANTIBODY AND CHIMERIC ANTIGEN RECEPTORS (CAR) AND THEIR USE
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114565761B (zh) * 2022-02-25 2023-01-17 无锡市第二人民医院 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法
CA3250590A1 (en) * 2022-06-09 2023-12-14 Telix Pharmaceuticals (Innovations) Pty Ltd POLYTHERAPY
KR20250158048A (ko) * 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド ヒト化ccケモカイン受容体4(ccr4)抗体およびその使用法
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
KR20170093248A (ko) 2014-12-19 2017-08-14 다나-파버 캔서 인스티튜트 인크. 탄산무수화효소 ix 특이적 키메라 항원 수용체 및 이의 사용 방법
US10738116B2 (en) * 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
WO2016174652A1 (en) * 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
JP7115982B2 (ja) * 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
PT3583129T (pt) 2017-02-14 2021-12-14 Kite Pharma Inc Moléculas de ligação a cd70 e seus métodos de uso
MA47613A (fr) 2017-02-22 2020-01-01 Aleta Biotherapeutics Inc Compositions et procédés de traitement du cancer
AU2019235900B2 (en) 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)